WESTLAKE CORP Executive Chairman Albert Chao reported RSU vesting and related share withholding. On February 17, he exercised 16,555 restricted stock units, which convert into common stock on a one-for-one basis, resulting in 16,555 common shares acquired at a stated price of $0.00 per share.
On February 18, 5,089 common shares were disposed of at $98.95 per share to satisfy tax obligations arising from the RSU vesting, rather than through an open-market sale. After these transactions, he directly owned 639,188 shares of Westlake common stock.
Westlake Corp executive Robert F. Buesinger reported equity award activity and related tax withholding. On February 17, 2026, 3,478 restricted stock units were exercised into the same number of common shares at $0.00 per share, reflecting the vesting of RSUs granted on February 17, 2023. Following this conversion, his direct common stock holdings rose to 38,410 shares. On February 18, 2026, 903 common shares valued at $98.95 per share were disposed of to cover tax obligations from the RSU vesting, reducing his direct holdings to 37,507 shares.
Westlake Corp executive Mark Steven Bender reported equity compensation activity involving restricted stock units (RSUs) and common stock. On February 17, 4,751 RSUs converted into an equal number of Westlake common shares at a stated price of $0.0000 per share. Following this derivative exercise, his direct common stock holdings increased to 61,719 shares.
On February 18, 1,209 common shares were disposed of through a tax-withholding transaction at $98.95 per share to satisfy tax obligations arising from the RSU vesting, as described in the footnotes. After this withholding, Bender directly holds 60,510 shares of Westlake common stock.
Westlake Corporation has completed its previously announced acquisition of the global compounding solutions businesses of the ACI/Perplastic Group. The company disclosed the closing through a press release dated January 5, 2026, which is furnished as Exhibit 99.1 under a Regulation FD disclosure. This step confirms that the transaction has moved from agreement to completion.
The furnished press release is not treated as filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities law filings unless specifically identified. No purchase price or financial terms are included in this disclosure.
Westlake Corp’s executive chairman and director reported an option exercise and share sales in the company’s common stock. On 12/22/2025, he exercised an employee stock option to acquire 81,673 shares of common stock at an exercise price of $44.42 per share, increasing his direct holdings.
That same day, he sold shares in several open-market transactions, including 9,711 shares at a weighted average price of $72.818, 30,604 shares at a weighted average price of $73.796, and 521 shares at a weighted average price of $74.443. A portion of the sale proceeds was used to pay the option strike price and related taxes. After these transactions, he directly owned 627,722 shares of Westlake Corp common stock, and the reported option position was reduced to zero.
A holder of 40,836 shares of common stock of WLK has filed a notice of proposed sale under Rule 144. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $3,004,365.77 and an approximate sale date of 12/22/2025. The filing states that these shares were acquired on 12/22/2025 through a stock option exercise for cash. The issuer reports 128,273,220 shares of this class outstanding, which serves as a baseline for the company’s equity.
Westlake Corporation has approved plans to shut several North American chlorovinyl and styrene production facilities, triggering significant restructuring costs. The closures include a PVC plant in Aberdeen, Mississippi with annual capacity of approximately 1 billion pounds of suspension PVC, VCM and diaphragm chlor-alkali units at its Lake Charles, Louisiana complex with capacities of about 910 million pounds of VCM, 825 million pounds of chlorine and 910 million pounds of caustic soda, and a styrene plant there with about 570 million pounds of capacity. Westlake plans to continue supplying customers from seven other North American chlorovinyl facilities.
The company expects total pre-tax costs of approximately $415 million from these shutdowns, consisting of about $357 million of noncash accelerated depreciation, amortization and asset write-off charges, $25 million of employee severance and separation costs, and $33 million of other plant shutdown costs. Operations at the affected facilities are expected to cease in December 2025 and result in a workforce reduction of roughly 295 employees, with most charges recognized in the fourth quarter of 2025 and related cash outflows occurring over several years. Westlake also shared a press release, investor presentation and conference call update tied to its Performance & Essential Materials profitability improvement plan.
Westlake Corp director reports routine equity award vesting and share acquisition. A board member converted 1,339 restricted stock units into 1,339 shares of Westlake common stock on December 10, 2025, shown as an "M" code transaction. The form reports these shares as directly owned after the transaction.
The restricted stock units were originally granted on December 10, 2024 and vested on the first anniversary of the grant. Each unit converts into one share of common stock at an exercise price of $0, reflecting standard director equity compensation rather than an open-market purchase. The derivative position now shows zero restricted stock units remaining after this vesting and settlement.
Westlake Corporation announced the pricing and the expiration/results of its previously announced cash tender offer for any and all of its outstanding 3.600% Senior Notes due 2026. The updates were disclosed via two press releases issued on November 10, 2025 and furnished as Exhibits 99.1 and 99.2.
The tender offer remains subject to the terms and conditions set forth in the Offer to Purchase dated November 4, 2025. The information was furnished under Regulation FD (Item 7.01) and is not deemed filed under the Exchange Act.
Westlake Corporation announced an underwritten public debt offering of $600 million 5.550% senior notes due 2035 and $600 million 6.375% senior notes due 2055, issued off its Form S-3 shelf. The offering is expected to close on November 6, 2025, subject to customary conditions.
The company expects approximately $1.185 billion in net proceeds (after underwriting discounts and commissions). Westlake plans to use the proceeds first to fund a concurrent tender offer for any and all of its 3.600% senior notes due 2026, of which $750 million was outstanding as of September 30, 2025. Any remaining proceeds will fund part of the purchase price for the pending acquisition of the global compounding solutions business of the ACI/Perplastic Group and for general corporate purposes, including working capital. The offering is not contingent on completing the acquisition or the tender offer.
The notes will be issued under Westlake’s existing indenture and a fifteenth supplemental indenture, which include covenants limiting certain secured debt, sale-leasebacks, and specified mergers or asset transfers, subject to significant exceptions.